Literature DB >> 15225102

Applications of array technology: melanoma research and diagnosis.

Sandeep Nambiar1, Alireza Mirmohammadsadegh, Annett Bär, Walter Bardenheuer, Gernot Roeder, Ulrich R Hengge.   

Abstract

A complex set of genetic alterations occurs within a cell in order to permit neoplastic transformation. Human cancers undergo a continuous development from benign to malignant states, as most thoroughly documented in the mole-to-melanoma transition. Several specific genetic and transcriptional events correlate with the prolonged multistep sequence from early to late clinical stages of the disease. High-throughput microarrays are being used in expression profiling analyses with the aim of discovering genes and their pathways, functional characterization of genes and tumor subclassification. There are, however, many potential pitfalls in the use of microarrays that result in false leads and erroneous conclusions. This review summarizes the current status of the application of microarray technology in melanoma research. It also attempts to outline some of the steps needed to develop the key features to be observed in developing diagnostic and prognostic classification systems based upon gene expression profiling. Copyright Future Drugs Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15225102     DOI: 10.1586/14737159.4.4.549

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  2 in total

1.  Gene network analyses point to the importance of human tissue kallikreins in melanoma progression.

Authors:  Waleska K Martins; Gustavo H Esteves; Otávio M Almeida; Gisele G Rezze; Gilles Landman; Sarah M Marques; Alex F Carvalho; Luiz F L Reis; João P Duprat; Beatriz S Stolf
Journal:  BMC Med Genomics       Date:  2011-10-27       Impact factor: 3.063

2.  Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays.

Authors:  N J W de Wit; J Rijntjes; J H S Diepstra; T H van Kuppevelt; U H Weidle; D J Ruiter; G N P van Muijen
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.